Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III trial of FG001 in Aggressive Brain Cancer

Next Previous
X
Search
Trial Profile

A Pivotal Phase III trial of FG001 in Aggressive Brain Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FG 001 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors FluoGuide

    • Most Recent Events

    • 08 Jan 2024 According to a FluoGuide media release, the company plans to advance FG001 into the first clinical trial for registration of FG001 in fluorescence guided surgery (FGS) of aggressive brain cancer, based on feedback from the U.S. Food and Drug Administration (FDA).
    • 08 Jan 2024 According to a FluoGuide media release, Clinical trial to be used for registration of FG001 in fluorescent guided surgery of aggressive brain cancer expected to start in 2025.
    • 08 Nov 2022 According to a FluoGuide media release, A first large scale batch for FG001 has now been successfully manufactured by PolyPeptide in preparation for this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top